Showing results (61-70 of 104) with videos related to
Sort By:
Pageof 11
JCO Precision Oncology|August 21, 2018
Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung CancerZofia Piotrowska, Mehlika Hazar-Rethinam, Coleen Rizzo, et al.Cancer Cell|December 19, 2012
Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer modelsRyan B Corcoran, Katherine A Cheng, Aaron N Hata, et al.Cancer Discovery|October 29, 2013
mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1Anthony C Faber, Erin M Coffee, Carlotta Costa, et al.Nature|August 12, 2021
Cycling cancer persister cells arise from lineages with distinct programsYaara Oren, Michael Tsabar, Michael S Cuoco, et al.Biorxiv : the Preprint Server for Biology|May 7, 2026
Dual inhibition of GTP-bound (ON) and GDP-bound (OFF) KRAS G12C suppresses PI3Kα and leads to potent tumor inhibitionKatherine Parker, Samar Ghorbanpoor, Wafa Malik, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2020
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung CancerIbiayi Dagogo-Jack, Satoshi Yoda, Jochen K Lennerz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2018
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung CancerJessica J Lin, Viola W Zhu, Satoshi Yoda, et al.Cancer Discovery|May 3, 2015
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR InhibitorZofia Piotrowska, Matthew J Niederst, Chris A Karlovich, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2025
STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20-Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer ModelsRaymond A Pagliarini, Jack A Henderson, Benjamin C Milgram, et al.Cell|February 7, 2025
GUK1 activation is a metabolic liability in lung cancerJaime L Schneider, Kiran Kurmi, Yutong Dai, et al.Pageof 11